NEW YORK (GenomeWeb) – Bio-Techne has signed a deal to gain access to B-MoGen Biotechnologies' gene-editing technology, the companies announced today. As part of the arrangement, Bio-Techne has also made an unspecified seed investment in B-MoGen.

Specific details about the technology were not disclosed, but B-MoGen offers genome modification services that use targeted nucleases to delete genes, exons, or genomic regions, or to insert specific sequences into the genome. The company has also filed a patent application on a single-step method for isolating gene-edited cells.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.

May
08
Sponsored by
Dovetail Genomics

This webinar will discuss a proximity ligation-based method for studying structural variation in formalin-fixed paraffin-embedded (FFPE) tissue.